Development of a highly stable and targetable nanoliposomal formulation of topotecan.

[1]  C. Benz,et al.  Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine , 2009, Cancer Chemotherapy and Pharmacology.

[2]  John W. Park,et al.  Improved Pharmacokinetics and Efficacy of a Highly Stable Nanoliposomal Vinorelbine , 2009, Journal of Pharmacology and Experimental Therapeutics.

[3]  John W. Park,et al.  Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. , 2008, Journal of pharmaceutical sciences.

[4]  Jianwei Zhu,et al.  Preclinical Manufacture of an Anti‐HER2 scFv‐PEG‐DSPE, Liposome‐Inserting Conjugate. 1. Gram‐Scale Production and Purification , 2008, Biotechnology progress.

[5]  T. Herzog,et al.  Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma , 2008, Expert review of anticancer therapy.

[6]  M. Bally,et al.  Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors , 2008, Clinical Cancer Research.

[7]  S. Strychor,et al.  Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Nonliposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts , 2007, Clinical Cancer Research.

[8]  S. Nicum,et al.  Topotecan for the treatment of small-cell lung cancer , 2007, Expert review of anticancer therapy.

[9]  Jennifer I. Hare,et al.  Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. , 2006, Anti-cancer agents in medicinal chemistry.

[10]  Anitha Thomas,et al.  Transition Metal-Mediated Liposomal Encapsulation of Irinotecan (CPT-11) Stabilizes the Drug in the Therapeutically Active Lactone Conformation , 2006, Pharmaceutical Research.

[11]  R. Pazdur,et al.  Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. , 2006, Oncology.

[12]  M. Bally,et al.  Copper-topotecan complexation mediates drug accumulation into liposomes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[13]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[14]  M. Berger,et al.  Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. , 2006, Neuro-oncology.

[15]  X Zhang,et al.  Effect of stealthy liposomal topotecan plus amlodipine on the multidrug‐resistant leukaemia cells in vitro and xenograft in mice , 2006, European journal of clinical investigation.

[16]  John W. Park,et al.  Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. , 2006, Cancer research.

[17]  M. Berger,et al.  Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. , 2006, Cancer research.

[18]  P. van Hoogevest,et al.  Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[19]  D. Spriggs,et al.  Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. , 2005, The oncologist.

[20]  C. Benz,et al.  Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes , 2005, Clinical Cancer Research.

[21]  Corrie Lynn Messerer,et al.  Liposomal Irinotecan , 2004, Clinical Cancer Research.

[22]  C. Benz,et al.  Development of ligand-targeted liposomes for cancer therapy , 2004, Expert opinion on therapeutic targets.

[23]  K. Edwards,et al.  An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Imran Ahmad,et al.  Development and characterization of a novel liposome-based formulation of SN-38. , 2004, International journal of pharmaceutics.

[25]  T. Allen,et al.  Ligand-targeted liposomal anticancer drugs. , 2003, Progress in lipid research.

[26]  Udo Greiser,et al.  Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. , 2003, Cancer research.

[27]  Ulrik B Nielsen,et al.  Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. , 2002, Biochimica et biophysica acta.

[28]  Bradley D. Anderson,et al.  Stable Supersaturated Aqueous Solutions of Silatecan 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin via Chemical Conversion in the Presence of a Chemically Modified β-Cyclodextrin , 2002, Pharmaceutical Research.

[29]  F. Chang,et al.  Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation , 2002, Anti-cancer drugs.

[30]  Ulrik B Nielsen,et al.  Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  S. Guichard,et al.  Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  M. Bally,et al.  Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. , 2000, Cancer research.

[33]  D. Baccanari,et al.  Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  D. Papahadjopoulos,et al.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.

[35]  A. Kuin,et al.  Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. , 1997, Cancer research.

[36]  L. Grochow,et al.  An overview of the clinical pharmacology of topotecan. , 1997, Seminars in oncology.

[37]  Dayan Ad.  Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). , 1996 .

[38]  N. Palepu,et al.  Preformulation studies to aid in the development of a ready-to-use injectable solution of the antitumor agent, topotecan , 1996 .

[39]  X. Gao,et al.  Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. , 1994, Journal of pharmaceutical sciences.

[40]  V. Stella,et al.  A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. , 1992, Journal of pharmaceutical sciences.

[41]  C. Osborne,et al.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.

[42]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[43]  G. R. Bartlett.  Phosphorus assay in column chromatography. , 1959, The Journal of biological chemistry.

[44]  H. Maeda,et al.  Macromolecular Therapeutics , 2003, Clinical pharmacokinetics.

[45]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[46]  J. Waldrep,et al.  Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice , 1999, Cancer Chemotherapy and Pharmacology.

[47]  B. Giovanella,et al.  Anticancer exffect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice , 1999, Cancer Chemotherapy and Pharmacology.

[48]  J. Verweij,et al.  Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. , 1997, British Journal of Cancer.

[49]  M. Muller,et al.  Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan. , 1995, Oncology research.

[50]  J. Beijnen,et al.  Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. , 1990, Journal of pharmaceutical and biomedical analysis.